Patents by Inventor Mark Litton

Mark Litton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7927863
    Abstract: Methods are provided for the synthesis and secretion of recombinant proteins preferably large mammalian proteins or hetero-multimeric proteins at high levels and for prolonged time in polyploid, preferably diploid yeast. These methods use various mating competent yeast, including Pichia. In a preferred embodiment, a first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.
    Type: Grant
    Filed: May 8, 2006
    Date of Patent: April 19, 2011
    Assignees: Alder BioPharmaceuticals, Inc., Keck Graduate Institute
    Inventors: James M. Cregg, John Latham, Mark Litton, Randall Schatzman, Ilya I. Tolstorukov
  • Publication number: 20100158859
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Application
    Filed: November 24, 2009
    Publication date: June 24, 2010
    Inventors: Jeffrey T.L. Smith, John Latham, Mark Litton, Randall Schatzman
  • Publication number: 20100150829
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.
    Type: Application
    Filed: November 24, 2009
    Publication date: June 17, 2010
    Inventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Olson, Ben Dutzar, John Latham, Brian Kovacevich, Jeffrey T.L. Smith, Mark Litton, Randall Schatzman
  • Publication number: 20080003643
    Abstract: Methods are provided for the synthesis and secretion of recombinant hetero-multimeric proteins in mating competent yeast. A first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.
    Type: Application
    Filed: October 22, 2004
    Publication date: January 3, 2008
    Inventors: James M. Cregg, John Latham, Mark Litton, Randall Schatzman, Ilya I. Tolstorukov
  • Publication number: 20060270045
    Abstract: Methods are provided for the synthesis and secretion of recombinant proteins preferably large mammalian proteins or hetero-multimeric proteins at high levels and for prolonged time in polyploid, preferably diploid yeast. These methods use various mating competent yeast, including Pichia. In a preferred embodiment, a first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.
    Type: Application
    Filed: May 8, 2006
    Publication date: November 30, 2006
    Applicants: Keck Graduate Institute, Alder Biopharmaceuticals, Inc.
    Inventors: James Cregg, John Latham, Mark Litton, Randall Schatzman, Ilya Tolstorukov